Exelixis reported a strong Q3 2025, with Net Product Revenues of \(542.9 million (up 14%) driven by CABOMETYX volume growth across RCC and new NET indications. Net Income surged 64% to \)193.6 million, leading to Diluted EPS of \(0.69. Year-to-date (YTD), Net Income reached \)538.0 million, and Diluted EPS was \(1.90. Operational cash flow grew robustly to \)550.8 million YTD.
The company is strategically focused on pipeline advancement, announcing positive top-line results for lead asset zanzalintinib in the STELLAR-303 (CRC) trial, showing a 20% risk reduction versus regorafenib. An NDA submissio
...